PDS Biotechnology Files 8-K for Other Events
Ticker: PDSB · Form: 8-K · Filed: Oct 29, 2025 · CIK: 1472091
| Field | Detail |
|---|---|
| Company | Pds Biotechnology Corp (PDSB) |
| Form Type | 8-K |
| Filed Date | Oct 29, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.00033 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-filing, administrative, pharmaceuticals
TL;DR
PDS Biotech filed an 8-K on 10/29/25 for other events and financials.
AI Summary
PDS Biotechnology Corporation filed an 8-K on October 29, 2025, to report other events and financial statements. The company, incorporated in Delaware, is based in Princeton, NJ, and operates in the pharmaceutical preparations sector. It was formerly known as Edge Therapeutics, Inc. before a name change on September 11, 2009.
Why It Matters
This filing indicates PDS Biotechnology is providing updates on its corporate activities and financial status, which could be relevant for investors monitoring the company's progress.
Risk Assessment
Risk Level: low — This 8-K filing is primarily administrative, reporting standard corporate events and financial statements without disclosing significant new risks or material changes.
Key Numbers
- 001-37568 — SEC File Number (Identifies the company's filing history with the SEC.)
- 26-4231384 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- PDS Biotechnology Corporation (company) — Registrant
- October 29, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- Princeton, NJ (location) — Principal Executive Offices
- Edge Therapeutics, Inc. (company) — Former Company Name
- September 11, 2009 (date) — Date of Name Change
FAQ
What specific 'Other Events' are being reported in this 8-K filing?
The provided text does not detail the specific 'Other Events'; it only lists 'Other Events' as an item information category.
What is the primary business of PDS Biotechnology Corporation?
PDS Biotechnology Corporation operates in the Pharmaceutical Preparations sector, with SIC code 2834.
When did PDS Biotechnology Corporation change its name from Edge Therapeutics, Inc.?
The company changed its name from Edge Therapeutics, Inc. on September 11, 2009.
Where are PDS Biotechnology Corporation's principal executive offices located?
The principal executive offices are located at 303A College Road East, Princeton, NJ 08540.
What is the filing date of this 8-K report?
The report was filed on October 29, 2025.
Filing Stats: 453 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2025-10-29 08:45:37
Key Financial Figures
- $0.00033 — ch registered Common Stock, par value $0.00033 per share PDSB The Nasdaq Capital M
Filing Documents
- ef20057871_8k.htm (8-K) — 27KB
- ef20057871_ex99-1.htm (EX-99.1) — 18KB
- image00003.jpg (GRAPHIC) — 3KB
- 0001140361-25-039656.txt ( ) — 179KB
- pdsb-20251029.xsd (EX-101.SCH) — 4KB
- pdsb-20251029_lab.xml (EX-101.LAB) — 21KB
- pdsb-20251029_pre.xml (EX-101.PRE) — 16KB
- ef20057871_8k_htm.xml (XML) — 4KB
01
Item 8.01 Other Events. On October 29, 2025, PDS Biotechnology Corporation issued a press release announcing that the Company has requested a meeting with the Food and Drug Administration to explore an expedited approval pathway for PDS0101 in HPV16+ Head and Neck Cancer. A copy of the press release is filed herewith as Exhibit 99.1 and incorporated by reference herein.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release Dated October 29, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document). Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PDS BIOTECHNOLOGY CORPORATION Date: October 29, 2025 By: /s/ Frank Bedu-Addo, Ph.D. Name: Frank Bedu-Addo, Ph.D. Title: President and Chief Executive Officer